← Leaderboards
Jorge Plutzky
Brigham And Women'S Hospital
$7,978,805
Attributed
$9,203,805
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$9,203,805 · 7
By mechanism
R01$4,511,219 · 3
P01$4,263,614 · 3
R56$428,972 · 1
Top collaborators
- Patrick Robert Griffin5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Dariush Mozaffarian$28,150,783
- Hyon K Choi$12,976,398
- Benjamin D Humphreys$13,400,455
- Wendy Y Chen$263,052
- Meir J Stampfer$56,174,887
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisIn VivoResponseFatty Acid Glycerol EstersFatty AcidsMetabolismPathway InteractionsEnzymesDiabetes MellitusMetabolicInsightBiologyReportingInflammationMediator Of Activation ProteinIn VitroInflammatory ResponseUptakeBlood VesselsProgramsDyslipidemiasEndothelial CellsObesityGenes
Grant awards (24)
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2021 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2020 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2019 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2018 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2017 · DK · contact PI
Epigenetic Control of Endothelial and T Cell States By BET Reader Proteins$428,972
R56 · FY2015 · HL · contact PI
THE ENDOTHELIAL PPARy-RXR TRANSCRIPTIONAL COMPLEX IN THE CONTROL OF METABOLISM$402,341
P01 · FY2014 · HL · contact PI
THE ENDOTHELIAL PPARy-RXR TRANSCRIPTIONAL COMPLEX IN THE CONTROL OF METABOLISM$390,847
P01 · FY2013 · HL · contact PI
THE ENDOTHELIAL PPARy-RXR TRANSCRIPTIONAL COMPLEX IN THE CONTROL OF METABOLISM$410,550
P01 · FY2012 · HL · contact PI
THE ENDOTHELIAL PPARy-RXR TRANSCRIPTIONAL COMPLEX IN THE CONTROL OF METABOLISM$410,550
P01 · FY2011 · HL · contact PI
THE ENDOTHELIAL PPARy-RXR TRANSCRIPTIONAL COMPLEX IN THE CONTROL OF METABOLISM$409,946
P01 · FY2010 · HL · contact PI
Modulation of Endogenous PPAR Activation$412,275
P01 · FY2009 · HL · contact PI
Modulation of Endogenous PPAR Activation$370,634
P01 · FY2008 · HL · contact PI
Lipolytic Mechanisms of PPAR Activation$395,272
R01 · FY2007 · HL · contact PI
Modulation of Endogenous PPAR Activation$391,548
P01 · FY2007 · HL · contact PI
Lipolytic Mechanisms of PPAR Activation$407,077
R01 · FY2006 · HL · contact PI
Modulation of Endogenous PPAR Activation$401,958
P01 · FY2006 · HL · contact PI
Endogenous Mechanisms of PPAR Modulation$425,122
R01 · FY2005 · HL
Lipolytic Mechanisms of PPAR Activation$416,874
R01 · FY2005 · HL
Modulation of Endogenous PPAR Activation$389,135
P01 · FY2005 · HL
Lipolytic Mechanisms of PPAR Activation$416,874
R01 · FY2004 · HL
MOLECULAR MECHANISMS OF THE METABOLIC SYNDROME$0
P01 · FY2002 · HL
MOLECULAR MECHANISMS OF THE METABOLIC SYNDROME$0
P01 · FY2001 · HL
MOLECULAR MECHANISMS OF THE METABOLIC SYNDROME$273,830
P01 · FY2000 · HL